Latest news with #Viz.ai
Business Wire
6 days ago
- Business
- Business Wire
Viz.ai Launches New Strategic Alliance to Accelerate Timely Diagnosis and Deliver AI-Powered Precision Care for Patients with Cancer
SAN FRANCISCO--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a new multi-year collaboration with Novartis aimed at transforming cancer care through the development of proprietary AI-powered workflows within the Viz Oncology Suite. This strategic alliance will focus on improving the identification and stratification of patients diagnosed with prostate and breast cancers based on key risk factors, accelerating access to guideline-based precision treatments. For patients with cancer, every day matters. Yet too often, diagnosis and treatment are delayed by fragmented systems, manual reviews, and complex care journeys. These inefficiencies can lead to missed diagnoses, delayed access to life-extending therapies, and worse outcomes. This collaboration aims to address that, using AI to help ensure patients are surfaced and treated earlier, with care that's timely, coordinated, and personalized. 'We are excited to be partnering with Novartis, an innovative medicines company and a leader in oncology, to accelerate access to timely, guideline-based care for patients facing prostate and breast cancer,' said Chris Mansi, MD, CEO and co-founder of 'This collaboration is part of our broader strategic expansion into oncology, furthering mission to fundamentally transform healthcare through intelligent care coordination.' As part of the collaboration will be developing two new AI-powered solutions: Viz Prostate Cancer, designed to streamline the identification of eligible patients for guideline-based treatment and support timely referrals to an appropriate specialist. Only one in four patients receives guideline-recommended therapy for prostate cancer, and thousands of patients with advanced disease who are eligible for potential life-extending treatments are never identified. 1,2 Viz Breast Cancer, designed to support breast oncologists by automating patient review, aggregating risk-relevant data, surfacing therapeutic guidelines, and facilitating coordination among multidisciplinary care teams. Breast cancer is the most widely diagnosed cancer in the United States, with patient care journeys that are complex, time-consuming, and often fragmented. 3 'Earlier diagnosis and interventions can positively impact patient outcomes. At Novartis, we lead the industry in fostering bold partnerships and initiatives that support early screening and diagnosis; we are also leveraging innovative, data-driven technologies to help connect patients with appropriate care as quickly as possible," said Rodney Gillespie, Head of Oncology, Novartis US. "By sharing key insights with we will develop AI-powered solutions to quickly help reach patients who could benefit from guideline-based targeted treatments for prostate and breast cancer, helping significantly expedite their care.' 'Too often, patients with cancer are identified late or fall through the cracks of an increasingly complex care system,' said Ethan M. Basch, MD, Chief of Oncology and Cancer Hospital Physician-in-Chief at UNC. 'AI-powered tools bring the potential to optimize how we detect, triage, and treat cancer—by delivering the right care, to the right patient, at the right time.' With this collaboration and expansion into oncology, is building on its commitment to create a connected, intelligent healthcare AI layer that delivers better care for every patient, everywhere. Learn more about Viz Oncology by visiting About Inc. is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit References Goebell PJ, Raina R, Chen SL, et al. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol. 2024;20(11):903-918. doi:10.2217/fon-2023-0814 Reynolds S. Many men with metastatic prostate cancer are not getting the recommended treatments, study finds. Cancer Currents Blog. February 18, 2025. Accessed April 21, 2025. American Cancer Society. How common is breast cancer? American Cancer Society. Accessed April 21, 2025.
Yahoo
28-05-2025
- Business
- Yahoo
Viz.ai Expands AI Cancer Care Tools with AI-Powered Viz Oncology™ Suite
Comprehensive suite of solutions designed to empower oncology care teams, accelerating patient diagnosis and treatment strategic expansion into new oncology service line, enhances the company's leadership in stroke care, cardiology, trauma, and radiology SAN FRANCISCO, May 28, 2025--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of the Viz Oncology™ Suite, a transformative platform designed to accelerate access to life-saving cancer care. This marks a strategic expansion of proven capabilities into oncology, building on the company's success in stroke, cardiology, respiratory, and radiology. "Cancer remains one of the most urgent and complex clinical challenges in medicine today, is proud to bring our advanced AI platform to support oncology teams," said Chris Mansi, MD, CEO and co-founder of "This expansion aligns with our mission to increase access to lifesaving treatments. We bring our proven success in time-sensitive specialties to oncology, identifying patients faster, getting them to the right specialist sooner and streamlining clinical workflow. With the Viz Oncology Suite, we are enabling a similar transformation in cancer care – one that is patient-centered, data-driven, and scalable." Cancer care is inherently complex – requiring the integration of vast amounts of longitudinal data, cross-specialty collaboration, and timely, guideline-directed interventions. Despite this complexity, oncology care pathways remain fragmented and highly manual, often leading to delays and variability in care that can compromise patient outcomes—especially outside of major cancer centers where resources and specialist access may be more limited. The Viz Oncology Suite addresses this critical gap by delivering an end-to-end AI solution that streamlines coordination, surfaces high-risk patients earlier, and helps ensure that every patient has timely access to the care they need. "Tools like the Viz Oncology Suite will bring AI-driven intelligence and automation to the front lines of oncology, enabling clinicians to identify and engage the right patients faster," said Sara Nunnery, MD, MSCI, Director of Breast Cancer Research at Tennessee Oncology. "By streamlining complex oncology workflows and care team coordination, this technology has the potential to enhance care delivery and ultimately improve outcomes for our patients in the community." The oncology service line represents one of the largest and fastest-growing areas in healthcare, projected to nearly double in revenue over the next decade. Yet, clinical need far outweighs the capacity of current systems. The Viz Oncology Suite helps close this gap, giving providers the tools to deliver timely, guideline-directed care and empowering them to manage a growing volume of complex cases with greater efficiency and precision. About Inc. is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit View source version on Contacts Media Contacts Carolyn Daniel Yunger / Daniel /
Business Wire
28-05-2025
- Business
- Business Wire
Viz.ai Expands AI Cancer Care Tools with AI-Powered Viz Oncology™ Suite
SAN FRANCISCO--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of the Viz Oncology™ Suite, a transformative platform designed to accelerate access to life-saving cancer care. This marks a strategic expansion of proven capabilities into oncology, building on the company's success in stroke, cardiology, respiratory, and radiology. 'Cancer remains one of the most urgent and complex clinical challenges in medicine today, is proud to bring our advanced AI platform to support oncology teams,' said Chris Mansi, MD, CEO and co-founder of 'This expansion aligns with our mission to increase access to lifesaving treatments. We bring our proven success in time-sensitive specialties to oncology, identifying patients faster, getting them to the right specialist sooner and streamlining clinical workflow. With the Viz Oncology Suite, we are enabling a similar transformation in cancer care – one that is patient-centered, data-driven, and scalable.' Cancer care is inherently complex – requiring the integration of vast amounts of longitudinal data, cross-specialty collaboration, and timely, guideline-directed interventions. Despite this complexity, oncology care pathways remain fragmented and highly manual, often leading to delays and variability in care that can compromise patient outcomes—especially outside of major cancer centers where resources and specialist access may be more limited. The Viz Oncology Suite addresses this critical gap by delivering an end-to-end AI solution that streamlines coordination, surfaces high-risk patients earlier, and helps ensure that every patient has timely access to the care they need. 'Tools like the Viz Oncology Suite will bring AI-driven intelligence and automation to the front lines of oncology, enabling clinicians to identify and engage the right patients faster,' said Sara Nunnery, MD, MSCI, Director of Breast Cancer Research at Tennessee Oncology. 'By streamlining complex oncology workflows and care team coordination, this technology has the potential to enhance care delivery and ultimately improve outcomes for our patients in the community.' The oncology service line represents one of the largest and fastest-growing areas in healthcare, projected to nearly double in revenue over the next decade. Yet, clinical need far outweighs the capacity of current systems. The Viz Oncology Suite helps close this gap, giving providers the tools to deliver timely, guideline-directed care and empowering them to manage a growing volume of complex cases with greater efficiency and precision. About Inc. is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit
Yahoo
21-05-2025
- Business
- Yahoo
Viz.ai, Sanofi and Regeneron to link for COPD management
is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution for improving the management of chronic obstructive pulmonary disease (COPD). The collaboration will focus on testing the usage of the care acceleration solution, the Viz COPD module, which will utilise electronic health record (EHR) data and AI for progressing the identification and management of COPD patients who are at elevated risk. COPD, a prevalent and progressive lung condition, causes restricted airflow and troubled breathing. The module is set to assess EHR data through natural language processing, aligning with established clinical guidelines to screen and triage subjects, and highlighting those at elevated risk for further care and follow-up. It is built upon the company's current presence across more than 1,700 health systems and hospitals, engaging more than 60,000 healthcare providers to enhance care and diagnosis in various diseases areas, including respiratory conditions. The partnership between the three parties is poised to increase patient impact, especially for those who would benefit significantly from enhanced care co-ordination. co-founder and CEO Chris Mansi stated: 'This collaboration with Sanofi and Regeneron is a major step forward in our mission to expand AI-driven care co-ordination across disease areas with critical unmet needs, such as COPD. Our approach aims to empower healthcare providers to deliver data-driven, guideline-directed care that meaningfully impacts patient outcomes. 'We look forward to collaborating with Sanofi and Regeneron to harness AI to accelerate advancements in disease management and improve patient access to care.' leverages machine learning and AI algorithms to expedite the diagnosis and care process across numerous hospitals and health systems in Europe and the US. One, an AI-powered intelligent care co-ordination solution, detects individuals with suspected diseases, supports critical decision-making and aids in improving the outcomes of patients. Supported by real-world clinical evidence, the solution delivers substantial value to providers, patients, pharma and medical device manufacturers. " Sanofi and Regeneron to link for COPD management" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management
Sanofi recently entered into a multi-year partnership with and Regeneron to develop an AI-powered solution for COPD management, reflecting its focus on innovation. Over the last month, the company's stock increased by 1.71%, paralleling broader market trends, which have seen modest gains amid easing trade concerns and strong corporate earnings. This stock movement coincides with Sanofi's robust Q1 earnings growth and a significant share buyback completion. The company's announcements of acquisitions and ongoing corporate strategies have likely complemented the market's positive sentiments, contributing to the slight rise in its share price. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. The recent partnership between Sanofi and emphasizes a commitment to innovation, potentially bolstering the company's growth narrative by enhancing its reputation in AI-powered medical solutions. This strategic move aligns with Sanofi's focus on expanding its market penetration through new product launches like Dupixent and vaccines, possibly influencing revenue and earnings positively. Analysts foresee a revenue growth of 4.3% annually over the next three years, driven by these strategic advancements, although competitive and regulatory pressures remain challenges. Over the last five years, Sanofi's total shareholder return, including dividends, was 28.21%, reflecting a reasonable performance in a volatile market. In the past year, Sanofi outperformed the French Pharmaceuticals industry with a return of 1%, compared to the industry's broader trends. Currently, Sanofi's share price of €95.9 sits at a discount to the consensus price target of €117.70, suggesting potential growth opportunities ahead. If the partnership proves successful, it could strengthen revenue and earnings projections, justifying the current price target estimates. Gain insights into Sanofi's future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
